These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 12639207)

  • 1. Statin Use and Severe Acute Liver Injury Among Patients with Elevated Alanine Aminotransferase.
    Verma SK; Huang J; Hutchinson HG; Estevez I; Kuang K; Reynolds SL; Schneeweiss S
    Clin Epidemiol; 2022; 14():1535-1545. PubMed ID: 36540900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apparent Hepatotoxicity of Giloy (
    Balkrishna A; Bhattacharya K; Sinha S; Dev R; Srivastava J; Singh P; Haldar S; Varshney A
    J Clin Exp Hepatol; 2022; 12(1):239-240. PubMed ID: 35068809
    [No Abstract]   [Full Text] [Related]  

  • 3. Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study.
    Beachler DC; de Luise C; Jamal-Allial A; Yin R; Taylor DH; Suzuki A; Lewis JH; Freston JW; Lanes S
    BMC Cancer; 2021 Jan; 21(1):97. PubMed ID: 33494720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAFLD/NASH in patients with type 2 diabetes and related treatment options.
    Radaelli MG; Martucci F; Perra S; Accornero S; Castoldi G; Lattuada G; Manzoni G; Perseghin G
    J Endocrinol Invest; 2018 May; 41(5):509-521. PubMed ID: 29189999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2 diabetes, smoking, insulin use, and mortality from hepatocellular carcinoma: a 12-year follow-up of a national cohort in Taiwan.
    Tseng CH
    Hepatol Int; 2013 Jun; 7(2):693-702. PubMed ID: 26201803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs.
    Saine ME; Carbonari DM; Newcomb CW; Nezamzadeh MS; Haynes K; Roy JA; Cardillo S; Hennessy S; Holick CN; Esposito DB; Gallagher AM; Bhullar H; Strom BL; Lo Re V
    BMC Pharmacol Toxicol; 2015 Apr; 16():8. PubMed ID: 25889498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events.
    Lo Re V; Carbonari DM; Forde KA; Goldberg D; Lewis JD; Haynes K; Leidl KB; Reddy RK; Roy J; Sha D; Marks AR; Schneider JL; Strom BL; Corley DA
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):676-83. PubMed ID: 25866286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with Diabetes Mellitus are Prone to Develop Severe Hepatitis and Liver Failure due to Hepatitis Virus Infection.
    Singh KK; Panda SK; Shalimar ; Acharya SK
    J Clin Exp Hepatol; 2013 Dec; 3(4):275-80. PubMed ID: 25755514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alogliptin: concern about hepatotoxicity?
    Scheen AJ
    Clin Pharmacokinet; 2014 Nov; 53(11):1057-9. PubMed ID: 25336393
    [No Abstract]   [Full Text] [Related]  

  • 10. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study.
    Wang MT; Lee WJ; Huang TY; Chu CL; Hsieh CH
    Br J Clin Pharmacol; 2014 Sep; 78(3):619-29. PubMed ID: 25279406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpreting observational studies: why empirical calibration is needed to correct p-values.
    Schuemie MJ; Ryan PB; DuMouchel W; Suchard MA; Madigan D
    Stat Med; 2014 Jan; 33(2):209-18. PubMed ID: 23900808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of case definitions for identifying acute liver injury in large observational databases.
    Katz AJ; Ryan PB; Racoosin JA; Stang PE
    Drug Saf; 2013 Aug; 36(8):651-61. PubMed ID: 23670723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced Liver Injury.
    David S; Hamilton JP
    US Gastroenterol Hepatol Rev; 2010 Jan; 6():73-80. PubMed ID: 21874146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.
    Tolman KG; Freston JW; Kupfer S; Perez A
    Drug Saf; 2009; 32(9):787-800. PubMed ID: 19670918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-induced liver injury: is it somehow foreseeable?
    Tarantino G; Di Minno MN; Capone D
    World J Gastroenterol; 2009 Jun; 15(23):2817-33. PubMed ID: 19533803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents.
    Chan KA; Truman A; Gurwitz JH; Hurley JS; Martinson B; Platt R; Everhart JE; Moseley RH; Terrault N; Ackerson L; Selby JV
    Arch Intern Med; 2003 Mar; 163(6):728-34. PubMed ID: 12639207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone.
    Graham DJ; Drinkard CR; Shatin D
    Am J Gastroenterol; 2003 Jan; 98(1):175-9. PubMed ID: 12526954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Troglitazone (Rezulin) and hepatic injury.
    Faich GA; Moseley RH
    Pharmacoepidemiol Drug Saf; 2001; 10(6):537-47. PubMed ID: 11828837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Troglitazone-associated hepatic failure.
    Booth AM; Caldwell SH; Iezzoni JC
    Am J Gastroenterol; 2000 Feb; 95(2):557-8. PubMed ID: 10685776
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.